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Transcatheter Aortic Valve Replacement
Focus IssueVasilis Babaliaros, MD, FACC, Associate Editor, JACC: Cardiovascular Interventions“Our wretched species is so made that those who
walk on the well-trodden path always throw
stones at those showing a new road.”
—Voltaire (1)
“If at ﬁrst the idea is not absurd,
then there will be no hope for it.”
—Albert Einstein (2)I t was the spring of 2005 in Rouen, France. Wecarefully looked over the data to try to assemblea cohesive, midterm results paper on the ﬁrst 36
patients who underwent a transcatheter aortic valve
replacement (TAVR). Ten years ago it was not called
TAVR and the procedure itself did not even have an
acronym, only a device: the percutaneous heart
valve. The patients were implanted using 2 different
approaches, and the delivery system was makeshift,
constructed out of available wires, balloons, and
sheaths. This was the world’s ﬁrst experience with
the new procedure, and the results were representa-
tive of early technology, with 59% mortality at
6 months (3).
In 2005 TAVR was nothing if not polarizing. It was
not uncommon to overhear members of the cardiaque
soins intensifs (cardiac care unit) staff discussing their
concerns about patient outcomes in the hallways.
There were serious doubts in the cardiac surgery
world about patient safety and whether catheter-
based valve replacement was even in the realm of
possibility. Still, there were the dreamers, those of us
who were encouraged by a procedure and a device
that could dramatically alter the scope and usefulness
of cardiac intervention. More importantly, patients
and their families believed enough in the promise of
this new therapy to take a risk.
Ten years later as I write this editorial, the proce-
dure now has 2 acronyms (TAVR/TAVI [transcatheter
aortic valve implantation] and all of the debates thatensue of replacement vs. implantation), prospective
randomized multicenter trials have been performed
with 2 different TAVR devices, there are 7 different
approaches for implantation and more than 7 dif-
ferent TAVR manufacturers, and JACC: Cardio-
vascular Interventions has a focus issue on TAVR with
9 original research papers. We have come a long way
in the last decade.
In JACC: Cardiovascular Interventions this month,
multiple registries report long-term data that is a
major improvement from the initial midterm results
reported in JACC. The Source XT registry reports
1-year mortality that is better than the 30-day data
from 10 years ago (3). The 5-year mortality from the
UK TAVI (United Kingdom Transcatheter Aortic Valve
Implantation) registry is 55%, besting 6-month mor-
tality reported with early experience (3). The hemo-
dynamics of TAVR are superior to the latest surgical
sutureless valves, and complication management
with stroke prevention devices and paravalvular leak
plugging have improved the safety of the procedure
even further. There is a greater understanding of the
effect of these devices on patients as reports of valve
thrombosis, recovery of von Willebrand multimers,
and ventricular improvement in patients with low
ﬂow, low gradient aortic stenosis with TAVR and
coronary revascularization emerge. In addition,
advanced imaging with cardiac computed tomogra-
phy has illuminated the interaction of the aortic
annulus with the newest TAVR technology and
possibly predicted long-term valve performance.
All of these reports are within 1 snapshot of JACC:
Cardiovascular Interventions this month.
So what is absurd about the idea of TAVR today?
Perhaps it is the fact that we still do not have any
prospective data on patients with intermediate sur-
gical risk and TAVR, although risk creep has been
occurring in Europe over the last 4 years. Perhaps it
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759is also that a low-risk trial comparing TAVR and sur-
gical aortic valve replacement has not already begun.
Perhaps it is that the only thing innovative in TAVR
today is a caval-aortic approach or the combination of
TAVR with other established procedures. It seems
that the innovative luster of TAVR has worn and has
not yet been replaced with another groundbreaking
procedure.
It is with relief, excitement, and some sadness that
I have watched TAVR develop and expand into the
mainstream over the past decade. To the skeptics,we say thank you. The adversity created by this group
has certainly fueled solutions to the problems
encountered with TAVR. As part of that initial group
of dreamers, I wait with anticipation for the rise of
another wave of transcatheter therapy that will
invigorate us for the next decade.
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